DK1879655T3 - Farmaceutisk sammensætning omfattende et antibakterielt middel og et aktivstof valgt blandt carveol, carvacrol, alfa-ionon, beta-ionon, og thymol - Google Patents
Farmaceutisk sammensætning omfattende et antibakterielt middel og et aktivstof valgt blandt carveol, carvacrol, alfa-ionon, beta-ionon, og thymol Download PDFInfo
- Publication number
- DK1879655T3 DK1879655T3 DK06744753.2T DK06744753T DK1879655T3 DK 1879655 T3 DK1879655 T3 DK 1879655T3 DK 06744753 T DK06744753 T DK 06744753T DK 1879655 T3 DK1879655 T3 DK 1879655T3
- Authority
- DK
- Denmark
- Prior art keywords
- active substance
- carveol
- antibiotic
- alone
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (8)
1. Farmaceutisk sammensætning kendetegnet ved at det omfatter: - mindst et første terapeutisk aktivstof, og - mindst et andet terapeutisk aktivstof der er et antibiotikum, hvor det første terapeutiske aktivstof er carveol og antibiotikummet er valgt blandt ampicillin, chloramphenicol, tetracyclin, streptomycin, erythromycin, polymyxin B og amoxicillin; eller det første terapeutiske aktivstof er carvacrol og antibiotikummet er valgt blandt amoxicillin, amoxicillin i forbindelse med clavulansyre, og rifampicin; eller det første terapeutiske aktivstof er alfa-ionon eller beta-ionon og antibiotikummet er cephazolin.
2. Sammensætning ifølge krav 1, kendetegnet ved at det første terapeutiske aktivstof er carveol og antibiotikummet er amoxicillin.
3. Sammensætning ifølge krav 1 eller 2, kendetegnet ved at de første og anden terapeutiske aktivstoffer er suspenderet i en vandig agaropløsning.
4. Sammensætning ifølge et hvilket som helst af kravene 1 til 3, kendetegnet ved at sammensætningen ikke omfatter detergent eller opløsningsmiddel.
5. Kit kendetegnet ved at det omfatter: - mindst en første beholder indeholdende et første terapeutisk aktivstof, og - mindst en anden beholder indeholdende et andet terapeutisk aktivstof der er et antibiotikum, hvor det første terapeutiske aktivstof er carveol og antibiotikummet er valgt blandt ampicillin, chloramphenicol, tetracyclin, streptomycin, erythromycin, polymyxin B og amoxicillin; eller det første terapeutiske aktivstof er carvacrol og antibiotikummet er valgt blandt amoxicillin, amoxicillin i forbindelse med clavulansyre, og rifampicin; eller det første terapeutiske aktivstof er alfa-ionon eller beta-ionon og antibiotikummet er cephazolin.
6. Kit ifølge krav 5, kendetegnet ved at det første terapeutiske aktivstof er carveol og antibiotikummet er amoxicillin.
7. Sammensætning ifølge et hvilket som helst af kravene 1 til 4 eller kit ifølge et hvilket som helst af kravene 5 til 6 til anvendelse i behandlingen af en infektion forårsaget af en bakterie hos en patient.
8. Sammensætning eller kit ifølge krav 7, kendetegnet ved at doser der skal administreres er: - mellem 10 og 200 mg/kg legemsvægt/dag af det første terapeutiske aktivstof, og - mellem 2 og 100 mg/kg legemsvægt/dag af det andet terapeutiske aktivstof af denne sammensætning.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2005/001313 WO2006120494A1 (fr) | 2005-05-13 | 2005-05-13 | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol |
| PCT/IB2006/001350 WO2006120567A2 (fr) | 2005-05-13 | 2006-05-15 | Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l'eugenol, le borneol et le carvacrol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1879655T3 true DK1879655T3 (da) | 2015-02-23 |
Family
ID=35427275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06744753.2T DK1879655T3 (da) | 2005-05-13 | 2006-05-15 | Farmaceutisk sammensætning omfattende et antibakterielt middel og et aktivstof valgt blandt carveol, carvacrol, alfa-ionon, beta-ionon, og thymol |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080214518A1 (da) |
| EP (1) | EP1879655B1 (da) |
| JP (1) | JP5410748B2 (da) |
| CN (3) | CN102319246B (da) |
| BR (1) | BRPI0610125B8 (da) |
| CA (1) | CA2606875C (da) |
| DK (1) | DK1879655T3 (da) |
| EA (1) | EA014069B1 (da) |
| ES (1) | ES2530963T3 (da) |
| MA (1) | MA29606B1 (da) |
| PT (1) | PT1879655E (da) |
| TN (1) | TNSN07424A1 (da) |
| WO (2) | WO2006120494A1 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2918571B1 (fr) * | 2007-07-10 | 2013-01-11 | Aroma Tech | Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales |
| EP2214656B1 (en) * | 2007-10-26 | 2018-12-05 | Avivagen Inc. | Compositions and methods for enhancing immune response |
| FR2925334A1 (fr) * | 2007-12-21 | 2009-06-26 | Ceva Sante Animale Sa | Nouvelles compositions antibacteriennes |
| AU2010242502B2 (en) | 2009-04-30 | 2016-11-10 | Avivagen Inc. | Methods and compositions for improving the health of animals |
| PL2480090T3 (pl) | 2009-09-24 | 2014-04-30 | Unilever Nv | Środek dezynfekujący zawierający eugenol, terpineol oraz tymol |
| CN103354741B (zh) | 2010-12-07 | 2016-01-13 | 荷兰联合利华有限公司 | 口腔护理组合物 |
| EP2773315B1 (en) | 2011-11-03 | 2015-07-08 | Unilever N.V. | A personal cleaning composition |
| EA026135B1 (ru) | 2011-12-06 | 2017-03-31 | Юнилевер Н.В. | Противомикробная композиция |
| CN102670598B (zh) * | 2012-05-08 | 2014-07-16 | 广东药学院 | 一种青霉素冰片组合物在制备抗菌药物中的应用 |
| CN102670619B (zh) * | 2012-05-08 | 2014-02-19 | 广东药学院 | 一种头孢氨苄冰片组合物 |
| CN103146255B (zh) * | 2013-02-25 | 2014-07-09 | 厦门吉宏包装科技有限公司 | 一种抑菌驱螨印刷底油母液和由母液制作的印刷底油及其制备方法 |
| CN105357971A (zh) * | 2013-05-07 | 2016-02-24 | 凯敏工业公司 | 含有香芹酚和麝香草酚的抗微生物组合物 |
| FR3025718A1 (fr) | 2014-09-15 | 2016-03-18 | Septeos | Antimicrobiens potentialises |
| FR3025719A1 (fr) | 2014-09-15 | 2016-03-18 | Septeos | Antimicrobiens potentialises |
| US10780294B2 (en) | 2014-11-19 | 2020-09-22 | The General Hospital Corporation | System and method for photo-dynamic procedure |
| JP6629327B2 (ja) * | 2014-12-18 | 2020-01-15 | ヘルパービー セラピューティクス リミテッドＨｅｌｐｅｒｂｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | 微生物感染の予防または治療で使用される組み合わせ |
| EP3233069A1 (en) * | 2014-12-18 | 2017-10-25 | Helperby Therapeutics Limited | Antimicrobial combinations and their use in the treatment of microbial infection |
| CN109512999B (zh) * | 2016-03-04 | 2022-05-10 | 广州英赛特生物技术有限公司 | 含氧碳氢衍生物的脂肪醇作为多粘菌素的协同增效剂的应用 |
| FR3048612B1 (fr) * | 2016-03-14 | 2020-10-02 | Septeos | Tulathromycine potentialisee |
| MA44286A (fr) | 2016-06-02 | 2019-01-09 | Advanced Scient Developements | Formulation pharmaceutique de cinéol et d'amoxicilline |
| GB201904963D0 (en) * | 2019-04-08 | 2019-05-22 | Anpario Plc | Composition for reducing antimicrobial resistance |
| US20220315860A1 (en) | 2019-12-04 | 2022-10-06 | Pranarom International S.A. | Method for transforming an essential oil |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4317775A (en) * | 1980-01-07 | 1982-03-02 | Hoffmann-La Roche Inc. | Amoxicillin derivatives |
| US5213615A (en) * | 1986-10-11 | 1993-05-25 | Ivoclar Ag | Dental material and method for the control of caries and paradentitis |
| DE3634697A1 (de) * | 1986-10-11 | 1988-04-21 | Dentaire Ivoclar Ets | Dentalwerkstoff zur bekaempfung von karies und parodontose |
| US5801153A (en) * | 1991-09-13 | 1998-09-01 | Badaway; Mohammed A. | Method of enhancing the antimicrobial properties of antibacterial antibiotics to massively control and prevent bacterial, fungal, and viral diseases in plants |
| FR2697133B1 (fr) * | 1992-10-28 | 1995-01-13 | Transbiotech | Composition biocide et/ou biostatique et ses applications. |
| US5308873A (en) * | 1992-12-18 | 1994-05-03 | Doyle E. Chastain | Method of killing yeast and fungi with carveol |
| CA2224227A1 (en) * | 1995-06-07 | 1996-12-19 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US6319507B1 (en) * | 1997-05-02 | 2001-11-20 | Kobo Products, Inc. | Agar gel bead composition and method |
| US6025400A (en) * | 1998-08-24 | 2000-02-15 | Marco Polo Technologies | Compositions for treatment of antibiotic-resistant gram-positive bacterial infections and methods for using and preparing the same |
| SE9901733L (sv) * | 1999-05-12 | 2000-11-13 | Akzo Nobel Nv | En komposition innehållande karvakrol och tymol för användning som bactericid |
| US6414036B1 (en) * | 1999-09-01 | 2002-07-02 | Van Beek Global/Ninkov Llc | Composition for treatment of infections of humans and animals |
| US6495512B1 (en) * | 2000-06-23 | 2002-12-17 | International Flavors & Fragrances Inc. | Salicylaldehyde-containing composition having antimicrobial and fragrancing properties and process for using same |
| US20020103261A1 (en) * | 2000-10-06 | 2002-08-01 | Dusan Ninkov | Compositions for injection or intravenous administration for the treatment of internal infection or inflammation in humans and animals |
| US6787568B1 (en) * | 2000-11-27 | 2004-09-07 | Phoenix Scientific, Inc. | Antibiotic/analgesic formulation and a method of making this formulation |
| EP1230917A1 (de) * | 2001-02-08 | 2002-08-14 | Vectron Therapeutics AG | Invasomen zur Therapie von Erkrankungen, ihre Herstellung und Verwendung |
| US6585963B1 (en) * | 2001-02-15 | 2003-07-01 | Watson Pharmaceuticals, Inc. | Nail compositions and methods of administering same |
| US20030180349A1 (en) * | 2001-12-07 | 2003-09-25 | Franklin Lanny U. | Respiratory infection prevention and treatment with terpene-containing compositions |
| US20030225003A1 (en) * | 2002-04-18 | 2003-12-04 | Dusan Ninkov | Antimicrobial therapeutic compositions for oral and topical use |
| US20060105000A1 (en) * | 2002-11-21 | 2006-05-18 | J.P.M.E.D. Ltd | Compositions for treating infected skin and mucous membrane comprising an anti-microbial agent and an essential oil |
| EA200500804A1 (ru) * | 2002-12-10 | 2005-12-29 | Биосинексус Инкорпорейтед | Топические противоинфекционные композиции |
| US20040151771A1 (en) * | 2003-02-04 | 2004-08-05 | Gin Jerry B. | Long-lasting, flavored dosage forms for sustained release of beneficial agents within the mouth |
| EP2338332B1 (en) * | 2004-05-20 | 2014-02-12 | Eden Research Plc | Hollow glucan particle or cell wall particle encapsulating a terpene component |
-
2005
- 2005-05-13 WO PCT/IB2005/001313 patent/WO2006120494A1/fr active Application Filing
-
2006
- 2006-05-15 EP EP06744753.2A patent/EP1879655B1/fr active Active
- 2006-05-15 US US11/914,015 patent/US20080214518A1/en not_active Abandoned
- 2006-05-15 CA CA2606875A patent/CA2606875C/fr active Active
- 2006-05-15 EA EA200702483A patent/EA014069B1/ru not_active IP Right Cessation
- 2006-05-15 CN CN2011101912078A patent/CN102319246B/zh active Active
- 2006-05-15 ES ES06744753T patent/ES2530963T3/es active Active
- 2006-05-15 PT PT67447532T patent/PT1879655E/pt unknown
- 2006-05-15 CN CN201310230786.1A patent/CN103356612B/zh active Active
- 2006-05-15 CN CN2006800164912A patent/CN101175531B/zh active Active
- 2006-05-15 BR BRPI0610125A patent/BRPI0610125B8/pt active IP Right Grant
- 2006-05-15 JP JP2008510671A patent/JP5410748B2/ja active Active
- 2006-05-15 DK DK06744753.2T patent/DK1879655T3/da active
- 2006-05-15 WO PCT/IB2006/001350 patent/WO2006120567A2/fr active Application Filing
-
2007
- 2007-11-13 TN TNP2007000424A patent/TNSN07424A1/fr unknown
- 2007-12-28 MA MA30530A patent/MA29606B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN103356612A (zh) | 2013-10-23 |
| JP2008540507A (ja) | 2008-11-20 |
| WO2006120567A3 (fr) | 2007-08-23 |
| CN102319246B (zh) | 2013-07-17 |
| ES2530963T3 (es) | 2015-03-09 |
| CN103356612B (zh) | 2015-04-15 |
| CN101175531B (zh) | 2011-09-07 |
| EP1879655B1 (fr) | 2014-11-26 |
| CN101175531A (zh) | 2008-05-07 |
| WO2006120567A2 (fr) | 2006-11-16 |
| TNSN07424A1 (fr) | 2009-03-17 |
| MA29606B1 (fr) | 2008-07-01 |
| BRPI0610125B8 (pt) | 2021-05-25 |
| CN102319246A (zh) | 2012-01-18 |
| CA2606875A1 (fr) | 2006-11-16 |
| JP5410748B2 (ja) | 2014-02-05 |
| BRPI0610125B1 (pt) | 2020-08-11 |
| PT1879655E (pt) | 2015-02-24 |
| CA2606875C (fr) | 2015-12-15 |
| BRPI0610125A2 (pt) | 2012-09-25 |
| EP1879655A2 (fr) | 2008-01-23 |
| EA200702483A1 (ru) | 2008-04-28 |
| US20080214518A1 (en) | 2008-09-04 |
| EA014069B1 (ru) | 2010-08-30 |
| WO2006120494A1 (fr) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1879655T3 (da) | Farmaceutisk sammensætning omfattende et antibakterielt middel og et aktivstof valgt blandt carveol, carvacrol, alfa-ionon, beta-ionon, og thymol | |
| JP6483058B2 (ja) | 抗菌剤と分散剤または接着阻害剤組成物 | |
| AU2003268330A1 (en) | Methods and reagents for treating infections of clostridium difficile and diseases associated therewith | |
| KR20070063036A (ko) | 감염의 치료에 대해 토탈 솔루션을 제공하는 항생제 배합물 | |
| CA2317748C (en) | Use of antimicrobial agent such as taurolidine or taurultam in the manufacture of a medicament to treat a nosocomial microbial infection | |
| JP6525999B2 (ja) | 抗菌性組成物 | |
| AU2013301576B2 (en) | Combinations with a backbone-cyclized peptide | |
| JP6626516B2 (ja) | 抗菌組成物及び方法 | |
| US20200093826A1 (en) | New use of triazolo(4,5 d)pyrimidine derivatives for prevention and treatment of bacterial infection | |
| JP6552648B2 (ja) | 抗菌組成物 | |
| RU2779346C2 (ru) | Антибактериальные композиции и способы | |
| KR20160138304A (ko) | 항균 물질들을 포함하는 약학 조성물 | |
| JP2017508769A (ja) | セフェピムまたはスルバクタムを含む医薬組成物 | |
| KR20140082451A (ko) | ＰＰＡＲδ 활성물질의 항생제, 화상 및 창상 치료제, 당뇨성 족부궤양 치료제로서의 용도 | |
| CN114432428A (zh) | PGLa提高细菌对抗生素的敏感性和延缓细菌耐药性产生的应用 | |
| CA3079023A1 (fr) | Utilisation de la cloxacilline pour inhiber/empecher la formation de biofilm |